Centers for Disease Control and Prevention

Quick facts

Marketed products

• Amodiaquine-artesunate (ASAQ) · Infectious Disease
  ASAQ is a fixed-dose combination of amodiaquine (a 4-aminoquinoline) and artesunate (an artemisinin derivative) that kills malaria parasites through complementary mechanisms involving heme detoxification disruption and rapid parasite clearance.
• amodiaquine plus artesunate
• amodiaquine plus sulfadoxine-pyrimethamine · Infectious Disease
  This combination inhibits parasite DNA synthesis and folate metabolism through complementary antimalarial mechanisms.
• Anthrax Vaccine Adsorbed
• AQAS · Infectious Disease Diagnostics
  AQAS is a quality assurance system used by the CDC to monitor and ensure the accuracy of laboratory test results for infectious diseases.
• Artemether+Lumefantrine (AL) · Infectious Disease
  Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing oxidative damage.
• bOPV (three dose) · Immunology / Infectious Disease
  bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis.
• bOPV (two dose) · Immunology / Infectious Disease
  bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis.
• chlorproguanil-dapsone plus artesunate · Infectious Disease
  This combination antimalarial drug works by inhibiting parasite dihydrofolate reductase (via chlorproguanil and dapsone) and disrupting mitochondrial function (via artesunate) to kill Plasmodium parasites through multiple pathways.
• fIPV (0.1 mL) ID · Immunology
  fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.
• fIPV (0.1mL) IM · Immunology / Infectious Disease
  fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection.
• fIPV (0.2mL) IM · Immunology / Infectious Disease
  fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing polio infection.
• fIPV at 6-14-22 weeks of age, Rotarix · Immunology
  fIPV (fractional-dose inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies against poliovirus and rotavirus, respectively, preventing infection and disease.
• fIPV at 6-14-22 weeks of age, RotaTeq
• FLUAD Quadrivalent · Immunology / Infectious Disease
  FLUAD Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
• Flublok™ Quadrivalent by Sanofi, Inc. · Immunology / Infectious Disease
  Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates the immune system to produce antibodies against four strains of influenza virus.
• Intradermal vaccine · Immunology
  Intradermal vaccines deliver immunogenic antigens into the dermis to stimulate local and systemic immune responses with potentially enhanced immunogenicity compared to intramuscular administration.
• IPV at 14 and 22 weeks of age, Rotarix · Immunology
  IPV (inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.
• IPV at 14 and 22 weeks of age, RotaTeq
• IPV at 14 and fIPV at 22 weeks, Rotarix
• IPV at 14 and fIPV at 22 weeks, RotaTeq · Immunology
  IPV (inactivated poliovirus vaccine) and RotaTeq (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.
• IPV at 6 and fIPV at 22 weeks, Rotarix · Immunology
  IPV (inactivated poliovirus vaccine) and fIPV (fractional dose IPV) stimulate immune responses against poliovirus types 1, 2, and 3, while Rotarix protects against rotavirus infection through live attenuated viral immunization.
• IPV at 6 and fIPV at 22 weeks, RotaTeq
• IPV at 6 weeks of age · Immunology / Infectious Disease
  IPV (Inactivated Poliovirus Vaccine) stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by introducing inactivated viral particles.
• lumefantrine-artemether · Infectious Disease
  Lumefantrine and artemether are antimalarial agents that work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and generating reactive oxygen species.
• lumefantrine plus artemether · Infectious Disease
  Lumefantrine and artemether work together as antimalarial agents that kill malaria parasites through distinct mechanisms involving heme detoxification and rapid parasite clearance.
• Mefloquine- Artesunate · Infectious Disease
  Mefloquine and artesunate work synergistically to kill malaria parasites through distinct mechanisms: mefloquine disrupts parasite membrane function while artesunate generates reactive oxygen species that damage parasite proteins and DNA.
• mOPV2 at 6 and 10 weeks of age
• mOPV2 at 6 and 7 weeks of age · Immunology / Infectious Disease
  mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.
• mOPV2 at 6 and 8 weeks of age · Immunology / Infectious Disease
  mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.
• Nuvaring · Other
• REZ · Oncology
  REZ is a monoclonal antibody that targets the CD19 protein on B cells.
• Sulfadoxine-pyrimethamine/folic acid · Infectious Disease
  Sulfadoxine-pyrimethamine inhibits dihydrofolate reductase and dihydropteroate synthase in parasites, blocking folate synthesis, while folic acid supplementation protects human cells from toxicity.
• VaxigripTetra™ by Sanofi, Inc. · Immunology / Infectious Disease
  VaxigripTetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
• Yellow Fever 17DD Vaccine · Immunology
  The Yellow Fever 17DD vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus by using a live attenuated (weakened) viral strain.

Phase 3 pipeline

• Arm E: f-IPV and bOPV · Immunology / Infectious Disease
  f-IPV and bOPV are inactivated and bivalent oral polio vaccines that stimulate immune responses against poliovirus types to prevent poliomyelitis infection.
• bOPV/IPV (14 weeks) · Infectious Disease
  bOPV/IPV is a vaccine that stimulates the body's immune response to protect against poliovirus and influenza.
• bOPV/IPV (6 & 14 weeks) · Infectious Diseases
  bOPV/IPV vaccine stimulates the body's immune response to produce antibodies against poliovirus and Haemophilus influenzae type b.
• bOPV/IPV (6 weeks) · Infectious Diseases
  bOPV/IPV is a vaccine that stimulates the body's immune response to protect against poliovirus and Haemophilus influenzae type b.
• FluQuadri · Immunology / Infectious Disease
  FluQuadri is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
• Group C: Inactivated Polio Vaccine · Immunology
  Inactivated Polio Vaccine stimulates the immune system to produce antibodies against poliovirus by introducing chemically inactivated (killed) virus particles.
• Infant nevirapine · Infectious Disease / Virology
  Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication in infants.
• JYNNEOS (Liquid Formulation) · Immunology / Infectious Disease
  JYNNEOS is a live attenuated vaccinia virus vaccine that stimulates immune responses against orthopoxviruses, including monkeypox and smallpox.
• Maternal zidovudine/lamivudine/lopinavir-ritonavir · Infectious Disease / Virology
  This combination of antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication in pregnant women and prevent mother-to-child transmission.
• rifapentine and moxifloxacin · Infectious Diseases
  Rifapentine is a bactericidal antibiotic that inhibits DNA-dependent RNA polymerase, while moxifloxacin is a bactericidal antibiotic that inhibits DNA gyrase and topoisomerase IV.

Phase 2 pipeline

• Doxycycline treatment
• doxyxcycline · Other
• Rifampin daily for 16 weeks
• Rifapentine daily for 6 weeks
• rVSVΔG-ZEBOV

Phase 1 pipeline

• 23-valent polysaccharide vaccine
• amodiaquine with artesunate
• antimicrobial agent in soap
• Artemether-lumefantrine: P. falciparum · Infectious Disease
  Artemether is a fast-acting antimalarial that acts by inhibiting the parasite's mitochondrial electron transport chain, while lumefantrine is a slow-acting antimalarial that acts by inhibiting the parasite's heme detoxification pathway.
• Artemether-Lumefantrine: P. vivax
• bivalent oral polio vaccine
• Chloroquine- P. vivax
• PCEC rabies vaccine administered intramuscularly
• PCEC rabies vaccine given intradermally
• sulfadoxine-pyrimethamine with artesunate
• Vaccination with inactivated polio vaccine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Centers for Disease Control and Prevention portfolio CI brief
• Centers for Disease Control and Prevention pipeline updates RSS